DE60035682T2
(de)
|
1999-04-28 |
2008-04-30 |
Sanofi-Aventis Deutschland Gmbh |
Di-aryl-säurederivate als ppar rezeptor liganden
|
TW200514783A
(en)
|
1999-09-22 |
2005-05-01 |
Bristol Myers Squibb Co |
Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
|
US6414002B1
(en)
|
1999-09-22 |
2002-07-02 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
AU2001272098A1
(en)
*
|
2000-03-09 |
2001-09-17 |
Sanofi-Aventis Deutschland Gmbh |
Therapeutic uses of PPAR mediators
|
JP2001261654A
(ja)
*
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
|
CA2429426A1
(en)
*
|
2000-11-17 |
2002-05-23 |
Takeda Chemical Industries, Ltd. |
Isoxazole derivatives
|
GB0029974D0
(en)
*
|
2000-12-08 |
2001-01-24 |
Glaxo Group Ltd |
Chemical compounds
|
US7238716B2
(en)
|
2000-12-28 |
2007-07-03 |
Takeda Pharmaceuticals Company Limited |
Alkanoic acid derivatives process for their production and use thereof
|
WO2002064632A2
(en)
*
|
2001-02-01 |
2002-08-22 |
Smithkline Beecham Corporation |
Crystallized ppar$g(a) ligand binding domain polypeptide and screening methods employing same
|
EP1394154A4
(en)
|
2001-03-23 |
2005-05-18 |
Takeda Pharmaceutical |
HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID
|
EP1375484A4
(en)
*
|
2001-03-28 |
2009-08-05 |
Eisai R&D Man Co Ltd |
CARBOXYLIC ACIDS
|
EP1375472A4
(en)
|
2001-03-30 |
2008-12-10 |
Eisai R&D Man Co Ltd |
BENZENE COMPOUND AND SALT THEREOF
|
TWI311133B
(en)
|
2001-04-20 |
2009-06-21 |
Eisai R&D Man Co Ltd |
Carboxylic acid derivativeand the salt thereof
|
US20030092736A1
(en)
*
|
2001-05-30 |
2003-05-15 |
Cheng Peter T. |
Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
|
GB0113231D0
(en)
|
2001-05-31 |
2001-07-25 |
Glaxo Group Ltd |
Chemical compounds
|
JPWO2002098840A1
(ja)
*
|
2001-06-04 |
2004-09-16 |
エーザイ株式会社 |
カルボン酸誘導体及びその塩もしくはそのエステルからなる医薬
|
DE60221391T2
(de)
|
2001-06-20 |
2008-04-17 |
Wyeth |
Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
|
TWI224101B
(en)
|
2001-06-20 |
2004-11-21 |
Wyeth Corp |
Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
|
AR036237A1
(es)
|
2001-07-27 |
2004-08-25 |
Bayer Corp |
Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
|
US20110065129A1
(en)
|
2001-07-27 |
2011-03-17 |
Lowe Derek B |
Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
|
EP1285914B1
(en)
*
|
2001-08-13 |
2007-12-19 |
PheneX Pharmaceuticals AG |
Nr1h4 nuclear receptor binding compounds
|
WO2003016265A1
(fr)
|
2001-08-17 |
2003-02-27 |
Eisai Co., Ltd. |
Compose cyclique et agoniste du recepteur ppar
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
IL160556A0
(en)
*
|
2001-08-31 |
2004-07-25 |
Aventis Pharma Gmbh |
Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
US6716842B2
(en)
|
2002-04-05 |
2004-04-06 |
Warner-Lambert Company, Llc |
Antidiabetic agents
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7078404B2
(en)
|
2002-04-11 |
2006-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
|
WO2003099793A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Takeda Pharmaceutical Company Limited |
1,2-azole derivatives with hypoglycemic and hypolipidemic activity
|
JP2004277397A
(ja)
*
|
2002-05-24 |
2004-10-07 |
Takeda Chem Ind Ltd |
1,2−アゾール誘導体
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
GB0214149D0
(en)
*
|
2002-06-19 |
2002-07-31 |
Glaxo Group Ltd |
Chemical compounds
|
SE0201937D0
(sv)
|
2002-06-20 |
2002-06-20 |
Astrazeneca Ab |
Therapeutic agents
|
US7351858B2
(en)
|
2002-06-20 |
2008-04-01 |
Astrazeneca Ab |
Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
|
ES2299702T3
(es)
|
2002-06-20 |
2008-06-01 |
Astrazeneca Ab |
Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
|
PL374860A1
(en)
|
2002-07-09 |
2005-11-14 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
JPWO2004007439A1
(ja)
*
|
2002-07-10 |
2005-11-10 |
住友製薬株式会社 |
ビアリール誘導体
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
NZ537603A
(en)
|
2002-07-12 |
2006-09-29 |
Sanofi Aventis Deutschland |
Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
|
US7297715B2
(en)
*
|
2002-07-30 |
2007-11-20 |
Merck & Co., Inc. |
PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
|
JP2004123732A
(ja)
*
|
2002-09-10 |
2004-04-22 |
Takeda Chem Ind Ltd |
5員複素環化合物
|
EP1541564A1
(en)
|
2002-09-10 |
2005-06-15 |
Takeda Pharmaceutical Company Limited |
Five-membered heterocyclic compounds
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
AU2003277576A1
(en)
|
2002-11-08 |
2004-06-07 |
Takeda Pharmaceutical Company Limited |
Receptor function controlling agent
|
EP1562915A1
(en)
|
2002-11-22 |
2005-08-17 |
SmithKline Beecham Corporation |
Farnesoid x receptor agonists
|
DE60306548T2
(de)
|
2002-12-10 |
2007-06-21 |
Wyeth |
Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
|
EP1569901B1
(en)
|
2002-12-10 |
2008-10-15 |
Wyeth |
ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
|
DE60306547T2
(de)
|
2002-12-10 |
2007-06-28 |
Wyeth |
Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator
|
UA80453C2
(en)
|
2002-12-10 |
2007-09-25 |
|
Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US6653334B1
(en)
*
|
2002-12-27 |
2003-11-25 |
Kowa Co., Ltd. |
Benzoxazole compound and pharmaceutical composition containing the same
|
WO2004063155A1
(en)
*
|
2003-01-06 |
2004-07-29 |
Eli Lilly And Company |
Fused heterocyclic derivatives as ppar modulators
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
US7196114B2
(en)
|
2003-02-17 |
2007-03-27 |
Sanofi-Aventis Deutschland Gmbh |
Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
|
DE10308355A1
(de)
*
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308353A1
(de)
*
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308350B4
(de)
*
|
2003-02-27 |
2006-06-01 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 1,3-Cyclohexandiol-Derivaten
|
DE10308354A1
(de)
*
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308351A1
(de)
*
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
DE10313228A1
(de)
*
|
2003-03-25 |
2004-10-21 |
Aventis Pharma Deutschland Gmbh |
Synthese von 2-Chlormethyl-6-methylbenzoesäureestern
|
US6989462B2
(en)
|
2003-03-25 |
2006-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Synthesis of 2-chloromethyl-6-methylbenzoic ester
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
US7244763B2
(en)
*
|
2003-04-17 |
2007-07-17 |
Warner Lambert Company Llc |
Compounds that modulate PPAR activity and methods of preparation
|
US7820837B2
(en)
|
2003-05-30 |
2010-10-26 |
Takeda Pharmaceutical Company Limited |
Condensed ring compound
|
US7348338B2
(en)
|
2003-07-17 |
2008-03-25 |
Plexxikon, Inc. |
PPAR active compounds
|
KR20130023381A
(ko)
|
2003-07-17 |
2013-03-07 |
플렉시콘, 인코퍼레이티드 |
Ppar 활성 화합물
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
JP5189765B2
(ja)
*
|
2003-08-01 |
2013-04-24 |
バイオコン・リミテッド |
加水分解可能なプロドラッグのためのアリールカルバメートオリゴマーおよびこれを含むプロドラッグ
|
DE10335450A1
(de)
*
|
2003-08-02 |
2005-02-17 |
Bayer Ag |
Indolin-Sulfanilsäureamide
|
WO2005012221A1
(ja)
*
|
2003-08-04 |
2005-02-10 |
Ono Pharmaceutical Co., Ltd. |
ジフェニルエーテル化合物、その製造方法および用途
|
BRPI0414130B8
(pt)
|
2003-09-03 |
2021-05-25 |
Askat Inc |
compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem.
|
CA2539016A1
(en)
*
|
2003-09-17 |
2005-03-24 |
Novartis Ag |
Organic compounds
|
US7411083B2
(en)
|
2003-09-25 |
2008-08-12 |
Wyeth |
Substituted acetic acid derivatives
|
US7442805B2
(en)
|
2003-09-25 |
2008-10-28 |
Wyeth |
Substituted sulfonamide-indoles
|
US7582773B2
(en)
|
2003-09-25 |
2009-09-01 |
Wyeth |
Substituted phenyl indoles
|
US7446201B2
(en)
|
2003-09-25 |
2008-11-04 |
Wyeth |
Substituted heteroaryl benzofuran acids
|
US7141592B2
(en)
|
2003-09-25 |
2006-11-28 |
Wyeth |
Substituted oxadiazolidinediones
|
US7332521B2
(en)
|
2003-09-25 |
2008-02-19 |
Wyeth |
Substituted indoles
|
US7268159B2
(en)
|
2003-09-25 |
2007-09-11 |
Wyeth |
Substituted indoles
|
US7351726B2
(en)
|
2003-09-25 |
2008-04-01 |
Wyeth |
Substituted oxadiazolidinediones
|
US7163954B2
(en)
|
2003-09-25 |
2007-01-16 |
Wyeth |
Substituted naphthyl benzothiophene acids
|
KR20060109925A
(ko)
|
2003-10-31 |
2006-10-23 |
얀센 파마슈티카 엔.브이. |
퍼옥시좀 증식체-활성화된 수용체(ppar) 이중작용제로서 유용한 페녹시아세트산 유도체
|
KR20060109926A
(ko)
|
2003-11-19 |
2006-10-23 |
메타베이시스 테라퓨틱스, 인크. |
새로운 인-함유 갑상선 호르몬 모방약들
|
EP1688138A4
(en)
|
2003-11-26 |
2008-01-16 |
Takeda Pharmaceutical |
AGENT FOR REGULATING THE FUNCTION OF A RECEIVER
|
US7238835B2
(en)
|
2003-12-22 |
2007-07-03 |
Sanofi-Aventis Deutschland Gmbh |
Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids
|
DE10360525B3
(de)
*
|
2003-12-22 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Herstellung von substituierten 2-(Phenoxymethyl)-benzoesäuren
|
EP1697339A1
(en)
|
2003-12-25 |
2006-09-06 |
Takeda Pharmaceutical Company Limited |
3-(4-benzyloxyphenyl)propanoic acid derivatives
|
US7585880B2
(en)
|
2003-12-26 |
2009-09-08 |
Takeda Pharmaceutical Company Limited |
Phenylpropanoic acid derivatives
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(de)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
EA011010B1
(ru)
|
2004-02-27 |
2008-12-30 |
Эмджен, Инк. |
Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
|
DE602004004631D1
(de)
|
2004-04-01 |
2007-03-22 |
Sanofi Aventis Deutschland |
Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
|
US7625949B2
(en)
|
2004-04-23 |
2009-12-01 |
Roche Palo Alto Llc |
Methods for treating retroviral infections
|
US7166738B2
(en)
|
2004-04-23 |
2007-01-23 |
Roche Palo Alto Llc |
Non-nucleoside reverse transcriptase inhibitors
|
WO2006004030A1
(ja)
*
|
2004-07-02 |
2006-01-12 |
Sankyo Company, Limited |
組織因子産生抑制剤
|
NZ552501A
(en)
|
2004-08-11 |
2010-03-26 |
Kyorin Seiyaku Kk |
Novel cyclic aminobenzoic acid derivative
|
DE102004039509B4
(de)
*
|
2004-08-14 |
2006-09-21 |
Sanofi-Aventis Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CN101039936A
(zh)
|
2004-08-23 |
2007-09-19 |
惠氏公司 |
作为i-型纤溶酶原激活剂抑制剂(pai-1)调节剂用于治疗血栓形成和心血管疾病的唑基-萘基酸
|
DE602005013272D1
(de)
*
|
2004-10-18 |
2009-04-23 |
Merck & Co Inc |
Diphenyl-substituierte alkane als flap-inhibitoren
|
WO2006046593A1
(ja)
|
2004-10-27 |
2006-05-04 |
Daiichi Sankyo Company, Limited |
2以上の置換基を有するベンゼン化合物
|
EP1829863A4
(en)
*
|
2004-11-26 |
2009-04-22 |
Takeda Pharmaceutical |
ARYLALCANOIC ACID DERIVATIVE
|
US7531568B2
(en)
|
2004-11-30 |
2009-05-12 |
Plexxikon, Inc. |
PPAR active compounds
|
JPWO2006101108A1
(ja)
*
|
2005-03-23 |
2008-09-04 |
杏林製薬株式会社 |
新規環状アミノフェニルアルカン酸誘導体
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
EP1919866A2
(en)
|
2005-08-17 |
2008-05-14 |
Wyeth a Corporation of the State of Delaware |
Substituted indoles and use thereof
|
KR20080042170A
(ko)
*
|
2005-09-07 |
2008-05-14 |
플렉시콘, 인코퍼레이티드 |
Ppar 활성 화합물
|
WO2007039177A2
(en)
|
2005-09-29 |
2007-04-12 |
Sanofi-Aventis |
Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
|
WO2007045573A1
(en)
|
2005-10-19 |
2007-04-26 |
F. Hoffmann-La Roche Ag |
Phenyl-acetamide nnrt inhibitors
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
PE20080993A1
(es)
|
2006-06-27 |
2008-10-06 |
Takeda Pharmaceutical |
Compuestos ciclicos fusionados como moduladores del receptor gpr40
|
MX2009002905A
(es)
*
|
2006-09-21 |
2009-06-19 |
Piramal Life Sciences Ltd |
Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos.
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
EP2125711B1
(en)
*
|
2007-03-08 |
2013-11-06 |
Albireo Ab |
3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
|
PE20090159A1
(es)
|
2007-03-08 |
2009-02-21 |
Plexxikon Inc |
COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
|
BRPI0701664A2
(pt)
*
|
2007-05-28 |
2009-01-13 |
Fundacao Universidade Fed De Sco Carlos |
4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CN101381302B
(zh)
*
|
2007-09-07 |
2013-04-03 |
上海睿智化学研究有限公司 |
2-溴甲基-6-甲基苯甲酰氯/溴的制备方法
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
AU2008338963A1
(en)
*
|
2007-12-13 |
2009-06-25 |
Sri International |
PPAR-delta ligands and methods of their use
|
US20110166132A1
(en)
*
|
2007-12-13 |
2011-07-07 |
Amgen Inc. |
Gamma Secretase Modulators
|
BRPI0907364A2
(pt)
|
2008-02-01 |
2015-07-14 |
Amira Pharmaceuticals Inc |
Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
|
WO2009102893A2
(en)
*
|
2008-02-14 |
2009-08-20 |
Amira Pharmaceuticals, Inc. |
CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
|
JP2011513242A
(ja)
|
2008-02-25 |
2011-04-28 |
アミラ ファーマシューティカルズ,インク. |
プロスタグランジンd2受容体アンタゴニスト
|
EP2268611A2
(en)
*
|
2008-04-02 |
2011-01-05 |
Amira Pharmaceuticals, Inc. |
Aminoalkylphenyl antagonists of prostaglandin d2 receptors
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
DE102008018675A1
(de)
|
2008-04-14 |
2009-10-15 |
Bayer Schering Pharma Aktiengesellschaft |
Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
|
KR101325367B1
(ko)
*
|
2008-07-03 |
2013-11-11 |
판미라 파마슈티칼스, 엘엘씨 |
프로스타글란딘 d2 수용체의 길항제
|
US8470841B2
(en)
|
2008-07-09 |
2013-06-25 |
Sanofi |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
AU2009270799B2
(en)
|
2008-07-18 |
2016-05-19 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
US8378107B2
(en)
|
2008-10-01 |
2013-02-19 |
Panmira Pharmaceuticals, Llc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
US8524748B2
(en)
|
2008-10-08 |
2013-09-03 |
Panmira Pharmaceuticals, Llc |
Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
|
US8383654B2
(en)
|
2008-11-17 |
2013-02-26 |
Panmira Pharmaceuticals, Llc |
Heterocyclic antagonists of prostaglandin D2 receptors
|
US20120004162A1
(en)
|
2008-12-04 |
2012-01-05 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
WO2013055385A2
(en)
|
2011-10-03 |
2013-04-18 |
Zafgen Corporation |
Methods of treating age related disorders
|
US8642650B2
(en)
|
2008-12-04 |
2014-02-04 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
US20100173313A1
(en)
*
|
2009-01-08 |
2010-07-08 |
Amira Pharmaceuticals, Inc. |
Biomarkers of inflammation
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
EP2440057A4
(en)
|
2009-06-09 |
2012-12-05 |
California Capital Equity Llc |
TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
|
EP2440053A4
(en)
|
2009-06-09 |
2012-10-31 |
California Capital Equity Llc |
BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
|
BRPI1011247A2
(pt)
|
2009-06-09 |
2016-06-21 |
California Capital Equity Llc |
derivados de isoquinolina, quinolina e quinazolina como inibidores de sinalização de hedgehog
|
CA2768587A1
(en)
*
|
2009-08-05 |
2011-02-10 |
Panmira Pharmaceuticals, Llc |
Dp2 antagonist and uses thereof
|
ES2443016T3
(es)
|
2009-08-26 |
2014-02-17 |
Sanofi |
Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
|
CA2774903A1
(en)
|
2009-10-02 |
2011-04-07 |
Sanofi |
Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
|
KR20120083905A
(ko)
*
|
2009-10-09 |
2012-07-26 |
자프겐 코포레이션 |
비만의 치료에 사용하기 위한 설폰 화합물
|
DE102009046115A1
(de)
*
|
2009-10-28 |
2011-09-08 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 3-Phenylpropansäuren und ihre Verwendung
|
AU2011203649A1
(en)
|
2010-01-06 |
2012-06-14 |
Brickell Biotech, Inc. |
DP2 antagonist and uses thereof
|
WO2011085198A1
(en)
|
2010-01-08 |
2011-07-14 |
Zafgen Corporation |
Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
|
BR112012016793A2
(pt)
|
2010-01-08 |
2018-07-31 |
Zafgen Corp |
compostos tipo fumagilol e métodos de fazer e usar os mesmos
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2011127304A2
(en)
|
2010-04-07 |
2011-10-13 |
Zafgen Corporation |
Methods of treating an overweight subject
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
ES2533065T3
(es)
|
2010-07-09 |
2015-04-07 |
Pfizer Limited |
Bencenosulfonamidas útiles como inhibidores de los canales de sodio
|
ES2526981T3
(es)
|
2010-07-12 |
2015-01-19 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
|
WO2012007883A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
US8772343B2
(en)
|
2010-07-12 |
2014-07-08 |
Pfizer Limited |
Chemical compounds
|
EP2593428B1
(en)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
ES2525581T3
(es)
|
2010-07-12 |
2014-12-26 |
Pfizer Limited |
Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
|
EP2595988B1
(en)
|
2010-07-22 |
2014-12-17 |
Zafgen, Inc. |
Tricyclic compounds and methds of making and using same
|
MY177039A
(en)
|
2010-11-09 |
2020-09-03 |
Zafgen Inc |
Crystalline solids of a metap-2 inhibitor and methods of making and using same
|
MX2013005989A
(es)
|
2010-11-29 |
2013-08-21 |
Zafgen Inc |
Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol.
|
MX2013006053A
(es)
|
2010-12-07 |
2013-06-18 |
Bayer Ip Gmbh |
Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso.
|
WO2012085745A1
(en)
|
2010-12-23 |
2012-06-28 |
Pfizer Inc. |
Glucagon receptor modulators
|
BR112013018771A2
(pt)
|
2011-01-26 |
2019-09-17 |
Zafgen Inc |
compostos de tetrazol e métodos para fazer e usar os mesmos
|
EA023517B1
(ru)
|
2011-02-08 |
2016-06-30 |
Пфайзер Инк. |
Модуляторы глюкагонового рецептора
|
JP5876513B2
(ja)
|
2011-03-08 |
2016-03-02 |
ザフゲン,インコーポレイテッド |
オキサスピロ[2.5]オクタン誘導体および類似体
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
DE102011007272A1
(de)
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
|
EP2705030B1
(en)
|
2011-05-06 |
2016-07-27 |
Zafgen, Inc. |
Partially saturated tricyclic compounds and methods of making and using same
|
BR112013028666A2
(pt)
|
2011-05-06 |
2017-08-08 |
Zafgen Inc |
compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
|
BR112013028665A2
(pt)
|
2011-05-06 |
2016-09-06 |
Zafgen Inc |
compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
|
CN103732578B
(zh)
|
2011-07-22 |
2015-08-12 |
辉瑞大药厂 |
喹啉基胰高血糖素受体调节剂
|
CN104066729A
(zh)
|
2011-08-15 |
2014-09-24 |
英特穆恩公司 |
溶血磷脂酸受体拮抗剂
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
CN104169268A
(zh)
|
2012-01-18 |
2014-11-26 |
扎夫根股份有限公司 |
三环砜化合物及其制备和使用方法
|
WO2013109739A1
(en)
|
2012-01-18 |
2013-07-25 |
Zafgen, Inc. |
Tricyclic sulfonamide compounds and methods of making and using same
|
BR112014027808A2
(pt)
|
2012-05-07 |
2017-06-27 |
Zafgen Inc |
sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
|
US9839622B2
(en)
|
2012-05-08 |
2017-12-12 |
Zafgen, Inc. |
Methods of treating hypothalamic obesity
|
EP2850079B1
(en)
|
2012-05-09 |
2018-05-02 |
Zafgen, Inc. |
Fumigillol type compounds and methods of making and using same
|
DE102012208530A1
(de)
|
2012-05-22 |
2013-11-28 |
Bayer Pharma AG |
Substituierte Piperidinoacetamide und ihre Verwendung
|
BR112015010223A2
(pt)
|
2012-11-05 |
2017-07-11 |
Zafgen Inc |
compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
|
JP2015536981A
(ja)
|
2012-11-05 |
2015-12-24 |
ザフゲン,インコーポレイテッド |
三環式化合物ならびにその製造および使用方法
|
US9561209B2
(en)
|
2012-11-05 |
2017-02-07 |
Zafgen, Inc. |
Methods of treating liver diseases
|
US9597309B2
(en)
|
2013-03-14 |
2017-03-21 |
Zafgen, Inc. |
Methods of treating renal disease and other disorders
|
AU2014237340C1
(en)
|
2013-03-15 |
2018-11-08 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
AU2014334554B2
(en)
|
2013-10-14 |
2018-12-06 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
MX363708B
(es)
|
2013-10-14 |
2019-03-29 |
Eisai R&D Man Co Ltd |
Compuestos de quinolina selectivamente sustituidos.
|
EA202092627A1
(ru)
|
2013-11-18 |
2021-09-30 |
Глобал Блад Терапьютикс, Инк. |
Соединения и их применения для модуляции гемоглобина
|
JP6699011B2
(ja)
*
|
2014-07-04 |
2020-05-27 |
国立大学法人 東京大学 |
脂肪酸サロゲートを含むリゾホスファチジルセリン誘導体
|
EP2982667A1
(en)
|
2014-08-04 |
2016-02-10 |
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. |
Competitive PPAR-gamma antagonists
|
BR112017005104B1
(pt)
|
2014-10-10 |
2022-08-23 |
Pulmocide Limited |
Derivados de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina, seus usos, composição farmacêutica e processo para a preparação dos mesmos
|
CN107257790A
(zh)
|
2014-12-18 |
2017-10-17 |
拜耳医药股份有限公司 |
取代的吡啶基‑环烷基‑羧酸、包含它们的组合物及其医学用途
|
US10160772B2
(en)
|
2014-12-18 |
2018-12-25 |
Pulmocide Limited |
5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
|
AR105671A1
(es)
|
2015-08-11 |
2017-10-25 |
Zafgen Inc |
Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
|
CN106432255A
(zh)
|
2015-08-11 |
2017-02-22 |
扎夫根公司 |
烟曲霉素醇螺环化合物和制备和使用其的方法
|
MA49566A
(fr)
|
2017-07-11 |
2020-05-20 |
Vertex Pharma |
Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
|
WO2019079222A1
(en)
*
|
2017-10-16 |
2019-04-25 |
Board Of Regents Of The University Of Texas System |
COMPOSITIONS FOR INHIBITING 3 'REPLACEMENT EXONUCLEASE 2 AND SCREENING METHODS FOR SUCH COMPOSITIONS
|
US10905667B2
(en)
|
2018-07-24 |
2021-02-02 |
Bayer Pharma Aktiengesellschaft |
Orally administrable modified-release pharmaceutical dosage form
|
CA3164134A1
(en)
|
2019-12-06 |
2021-06-10 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofurans as modulators of sodium channels
|
IL308953A
(en)
|
2021-06-04 |
2024-01-01 |
Vertex Pharma |
N-Hydroalkyl(Hetero)Aryl)Tetrahydrofuran Carboxamides as Natrene Channel Modulators
|
WO2024039864A1
(en)
*
|
2022-08-19 |
2024-02-22 |
Purdue Research Foundation |
Protein:protein interaction inhibitors
|